Rare disease drugmaker · based in Brisbane, United States · founded 1995 · ticker SGMOQ · sangamo.com
Sangamo Therapeutics works on 3 rare diseases we track, including Fabry Disease, Sickle Cell Disease and 1 more. It has 4 active clinical trials, though none are looking for new volunteers right now.
Sangamo Therapeutics develops gene therapies using its zinc finger nuclease (ZFN) platform. On June 23, 2026, Sangamo filed for Chapter 11 bankruptcy protection (District of Delaware) and entered stalking-horse asset-purchase agreements.
Sangamo Therapeutics pipeline
Each row lists the diseases Sangamo Therapeutics is studying at that stage, from the ones closest to approval down to the earliest work.
Phase 1
First studies in people, mostly checking safety.
HIV
Other studies
Studies with no phase listed, such as registries and natural history studies.
These are Sangamo Therapeutics trials for the rare diseases we track, from ClinicalTrials.gov. Statuses there can lag behind company news, so confirm with the study team before you plan around one.
4 trials underway, not taking new volunteers
Underway, not taking new volunteersPhase 1Recently updatedNCT02500849
Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients
TestsSB-728mR-HSPC Infusion 3 days following busulfan conditioning
For HIV
The purpose of the study is to evaluate the safety and feasibility of administering SB-728mR-HSPC after conditioning with busulfan.
Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 5 years following ST-920infusion.
Underway, not taking new volunteersNo updates in a whileNCT05987527
Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)
TestsBlood sample
For Kidney Transplant Rejection and End Stage Renal Disease
This long-term follow-up study is being conducted to collect long-term (up to 15 years post-infusion) safety and tolerability data from subjects enrolled in studies evaluating TX200-TR101.
Underway, not taking new volunteersHasn't posted an update in over a yearNCT05145062
Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.
TestsBIVV003, ST-400
For Blood and Lymphatic Diseases
Primary Objectives:
Long-term safety of BIVV003 in participants with severe sickle cell disease (SCD) and ST- 400 in participants with transfusion-dependent beta-thalassemia (TDT)
Secondary Objectives:
* Long-term efficacy of the biological treatment effect of BIVV003 in SCD
* Long-term efficacy of the clinical treatment effect of BIVV003 on SCD-related clinical events
* Long-term efficacy of the biological treatment effect of ST-400 in TDT
* Long-term efficacy of the clinical treatment effect of ST-400 in TDT
Follow a condition Sangamo Therapeutics is studying
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Sangamo Therapeutics. Unsubscribe anytime.
You'll get, for Fabry Disease:
Trial Alerts, when a new trial opens or a trial changes
Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
Following a court-supervised auction, Sangamo completed the sale of its platform technologies to Eli Lilly on September 4, 2026 for $50 million in cash, covering its AAV capsid engineering platform (including the STAC-BBB capsid), its zinc finger protein platform, its Modular Integrase genome editing platform, and its ST-506 prion disease program.
Its Fabry disease program ST-920 (isaralgagene civaparvovec) was sold to PTC Therapeutics, which outbid stalking-horse bidder Astellas at the court-supervised auction and completed the acquisition on September 21, 2026 for $111 million in cash plus up to $100 million in FDA-approval milestones. PTC expects to complete the rolling BLA (accelerated approval pathway) in Q4 2026.
Sangamo's common stock was suspended from Nasdaq on May 5, 2026 and now trades on the OTCID Basic Market under the symbol SGMOQ.
Where Sangamo Therapeutics trials take place
The trials above run at 30 study sites in 7 countries. Tap a country to see its states, cities and hospitals.
United States
20▼
United Kingdom
3▼
Netherlands
3▼
Australia
1▼
Canada
1▼
Germany
1▼
Belgium
1▼
Rare diseases Sangamo Therapeutics works on
Each disease page lists every open trial, not only Sangamo Therapeutics's, plus approved treatments.
Fabry disease is a rare inherited lysosomal storage disorder where a missing enzyme causes fatty substances called globotriaosylceramide to accumulate in cells throughout the body.
How common: 1 in 40,000 to 60,000 males; higher in females when accounting for carrier status
Sickle cell disease is an inherited blood disorder where hemoglobin polymerizes under low oxygen, causing red blood cells to become rigid, sickle-shaped, and prone to hemolysis and vaso-occlusion.
How common: About 100,000 Americans with SCD; about 1 in 365 Black or African American births and 1 in 16,300 Hispanic American births
Thalassemia is an inherited blood disorder where reduced or absent production of one type of hemoglobin chain causes anemia, from mild or none in carriers to severe in the major forms, where it can...
How common: About 1 in 100,000 people have symptoms of beta thalassemia, according to NORD, most often people with Mediterranean, Middle Eastern, African or Asian roots
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Sangamo Therapeutics's own site is sangamo.com, and our help paying for treatment page lists drugmaker programs and charity funds.
2 shared diseases, including Sickle Cell Disease and Thalassemia
Questions about Sangamo Therapeutics
Sangamo Therapeutics develops gene therapies using its zinc finger nuclease (ZFN) platform. On June 23, 2026, Sangamo filed for Chapter 11 bankruptcy protection (District of Delaware) and entered stalking-horse asset-purchase agreements. Following a court-supervised auction, Sangamo completed the sale of its platform technologies to Eli Lilly on September 4, 2026 for $50 million in cash, covering its AAV capsid engineering platform (including the STAC-BBB capsid), its zinc finger protein platform, its Modular Integrase genome editing platform, and its ST-506 prion disease program. Its Fabry disease program ST-920 (isaralgagene civaparvovec) was sold to PTC Therapeutics, which outbid stalking-horse bidder Astellas at the court-supervised auction and completed the acquisition on September 21, 2026 for $111 million in cash plus up to $100 million in FDA-approval milestones. PTC expects to complete the rolling BLA (accelerated approval pathway) in Q4 2026. Sangamo's common stock was suspended from Nasdaq on May 5, 2026 and now trades on the OTCID Basic Market under the symbol SGMOQ.
Sangamo Therapeutics has active programs across 3 rare diseases: Fabry Disease, Sickle Cell Disease, Thalassemia. Each disease page on Trial Friend shows the latest recruiting trials, FDA-approved treatments, and patient resources.
Yes. Sangamo Therapeutics is a rare disease specialist headquartered in Brisbane, United States, founded in 1995. The company focuses primarily on developing treatments for rare and orphan diseases, with programs targeting Fabry Disease, Sickle Cell Disease, Thalassemia.
The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Sangamo Therapeutics, pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.
To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.
None that we track as of November 2026. No Sangamo Therapeutics label in the FDA's openFDA database matches a rare disease on Trial Friend, which usually means the company has no approved product yet or its approved drugs are for common conditions.
In development: the trials list on this page shows what Sangamo Therapeutics is recruiting for now, and the FDA calendar lists any application once a decision date is public.
Sangamo Therapeutics was founded in 1995 and is headquartered in Brisbane, United States. The company has been active for 31 years. It trades publicly under the ticker symbol SGMOQ. As a rare disease specialist, the company dedicates its resources to developing therapies for patients with rare and orphan conditions.